Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AtDvance long-term extension study of GSK1070806 in moderate to severe atopic dermatitis
2023-508474-29-00Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 2, open-label, single-arm trial of aletekitug in atopic dermatitis (AD), sponsored by GSK. Started Jul 2024; status: completed.
02
Drugs
aletekitug
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2023-508474-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508474-29-00.